Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics

This is a research article published on January 16, 2019, in Frontiers in Psychiatry, titled "Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics" by Antonio Ventriglio et al. The study aimed to compare the risk of metabolic syndrome (MetS) in patients with chronic psychotic disorders (schizophrenia and schizoaffective disorder) treated with oral or long-acting injected (LAI) antipsychotics. The results showed that factors associated with MetS included antipsychotic drug dose, "high-risk" antipsychotics associated with weight-gain, older age, and female sex. The risk of MetS with antipsychotics ranked: quetiapine ≥ clozapine ≥ paliperidone ≥ olanzapine ≥ risperidone ≥ haloperidol ≥ aripiprazole. Other associated risk factors in multivariate modeling ranked: higher antipsychotic dose, older age, and schizoaffective disorder diagnosis, but not oral vs. LAI antipsychotics. In conclusion, schizoaffective disorder diagnosis and higher antipsychotic doses were associated with MetS, whereas orally vs. injected antipsychotics did not differ in risk of MetS.